Weight gain in asian patients on second-generation antipsychotics

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 2, 2010, Pages 118-121

  Mahendran, Rathi ^a   Hendricks, M ^a   Chan, Yiong Huak ^b  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Atypical antipsychotic medication; Physical monitoring

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; ASIAN; DIET; FEMALE; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PHYSICAL PARAMETERS; PSYCHOEDUCATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 77949528926     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Allison DB, Casey DE.Antipsychotic induced weight gain: a review of the literature. J Clin Psych 2001;62(Suppl 7):22-31.
2. Allison DB, Mentore JL, Heo M, Chandler P, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psych 1999;136:1688-96.
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
4. Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007;27:246-51.
5. Lee E, Leung CM, Wong E. Atypical anti-psychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychiatry 2004;65:864-6.
6. Lee C, Wu KH, Habel H, Dyaclikova Y, Lee P. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with Schizophrenia. Aust N Z J Psychiatry 2006;40:437-45.
7. Hwang TJ, Lee SM, Sun HJ, Lin HN, Tsai SJ, Lee YC, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formosa Med Assoc 2003;102:30-6.
8. Lee CT, Conde BJ, Mazlan M, Visanuyothin T, Wang A, Wong MM, et al. Switching to olanzapine from previous anti-psychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 2002;63:569-76.
9. Hwang TJ, Lin SK, Lin HN. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formosa Med Assoc 2001;100:811-6.
10. Suddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone and haloperidol treatment on weight and body mass index in first episode schizophrenia patients in India: a randomized, double-blind controlled prospective study. J Clin Psychiatry 2007;68:1793-8.
11. WHO expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
12. Ministry of Health, Singapore. Professional Circular No. 15A/2005. New BMI Categories for Public Health Action. Singapore: Ministry of Health.
13. International Diabetes Federation Available at www.idf.org. Accessed 13 May 2009.
14. National Health Survey 2004. Singapore: Epidemiology and Disease Control Department, Ministry of Health, 1999.
15. International Obesity Taskforce and the European Association for the Study of Obesity in Europe: the case for action. IOTF collaboration with EASO. London September 2002 (on line). Available at www.easoobesity.org. Accessed 13 May 2009.
16. Brown S, Inskip H, Barraclugh B. Causes of excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-7.
17. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-8.
18. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, et al. Estimating the consequences of antipsychotic induced weight gain of health and mortality RATE. Psychiatry Res 2001;101:277-88.
19. Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garcia-Potilla MP, Fernandez I, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003;62:77-88.
20. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007:68:8-13.
21. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pasdag J, et al. Novel anti-psychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
22. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;62:23-9.
23. Llorente MD, Urrutia V. Diabetes, Psychiatric disorders and the metabolic effects of antipsychotic medications. Clin Diabetes 2006;24:18-24.
24. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3-16.